Inflammation in cystic fibrosis - When and why? Friend or foe?

被引:8
作者
Elston, Caroline [1 ]
Geddes, Duncan [1 ]
机构
[1] Royal Brompton Hosp, Dept Resp Med, London SW3 6NP, England
关键词
cystic fibrosis; inflammation; host defense;
D O I
10.1055/s-2007-981649
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Pulmonary infection and an excessive neutrophil-driven inflammatory response are responsible for most of the morbidity and mortality associated with cystic fibrosis. Although inflammation is first and foremost a protective response to injury or infection it has the potential to cause considerable harm when it is excessive. Whereas most published reports emphasize the damaging effects of the chronic inflammatory response in cystic fibrosis, the beneficial effects are more difficult to quantify. Low levels of inflammation may assist in clearing infection, particularly early in the disease process, and surges of acute inflammation may be beneficial during exacerbations. Anti-inflammatory therapies are used to modify the inflammatory response but there is clearly a need to preserve the protective aspects of the inflammatory response because host defense and a fine balance exist between benefit and harm. The underlying processes involved in the inflammatory response are reviewed along with current and future anti-inflammatory therapies.
引用
收藏
页码:286 / 294
页数:9
相关论文
共 97 条
  • [91] Response to acute lung infection with mucoid Pseudomonas aeruginosa in cystic fibrosis mice
    van Heeckeren, AM
    Schluchter, MD
    Xue, W
    Davis, PB
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (03) : 288 - 296
  • [92] Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice
    Velsor, LW
    Van Heeckeren, A
    Day, BJ
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2001, 281 (01) : L31 - L38
  • [93] Wiesemann HG, 1998, PEDIATR PULM, V25, P88, DOI 10.1002/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO
  • [94] 2-J
  • [95] Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial
    Wolter, J
    Seeney, S
    Bell, S
    Bowler, S
    Masel, P
    McCormack, J
    [J]. THORAX, 2002, 57 (03) : 212 - 216
  • [96] Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis -: art. no. CD004197.pub2
    Wood, DM
    Smyth, AR
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [97] Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype
    Yarden, J
    Radojkovic, D
    De Boeck, K
    Macek, M
    Zemkova, D
    Vavrova, V
    Vlietinck, R
    Cassiman, JJ
    Cuppens, H
    [J]. THORAX, 2005, 60 (04) : 320 - 325